glp 1 and antipsychotics Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist—protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol Could GLP-1 Help Explain Antipsychotic-Related
Description
NICE, founded in 1999, sets explicit costeffectiveness thresholds (historically about 20,00030,000 per QALY gained, recently raised to 25,00035,000 from 2026 ( [3] ) ( [4] )) and mandates reimbursement for approved drugs in the singlepayer NHS
Other GLP-1 RAs have also shown varying benefits in clinical trials and are summarized in Table 1
What if I increase my semaglutide dose but still plateau
Clin Mol Hepatol (2013) 19(3):2105
